Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: Results from ERCHIVES

Liver International

Volumn 36, Issue 5, 2016, Pages 651-658

  Butt, Adeel A ^a,b,c,d   Yan, Peng ^a   Shaikh, Obaid S ^a,d   Chung, Raymond T ^e,f   Sherman, Kenneth E ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Hamad Healthcare Quality Institute   (Qatar)

^c HAMAD MEDICAL CORPORATION   (Qatar)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

ERCHIVES; SVR; DAA; Ledipasvir; Real life; Simeprevir; Sofosbuvir

Indexed keywords

ALBUMIN; BOCEPREVIR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL ABUSE; ALCOHOLISM; ANEMIA; ARTICLE; BLACK PERSON; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG ABUSE; DRUG DEPENDENCE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUTROPENIA; NEUTROPHIL COUNT; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; AGED; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; COMORBIDITY; FACTUAL DATABASE; HEPACIVIRUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; UNITED STATES;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COMORBIDITY; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES;

EID: 84952673661     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13036     Document Type: Article

References (20)

1. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015; 2: 691-700.
2. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
3. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54: 96-104.
4. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
5. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7.
6. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 14: 10.
7. Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-53.
8. Backus L, Belperio P, Shahoumian T, Mole L. Effectiveness of Sofosbuvir-Based Hepatitis C (HCV) Antiviral Regimens in a Large U.S. Veteran Cohort. Digestive Disease Week, May 16-19, 2015, Washington, DC, 2015.
9. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid Medical and Psychiatric Illness and Substance Abuse in HCV-infected and Uninfected Veterans. J Viral Hepatitis 2007; 14: 890-6.
10. Butt AA, Wang X, Budoff M, et al. Hepatitis C Virus Infection and the Risk of Coronary Disease. Clin Infect Dis 2009; 49: 225-32.
11. Butt AA, Wang X, Moore CM. Effect of HCV and Its Treatment upon Survival. Hepatology 2009; 50: 387-92.
12. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C Treatment Completion Rates in Routine Clinical Care. Liver Int 2009; 30: 240-50.
13. Butt AA, Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease. Am J Kidney Dis 2011; 57: 396-402.
14. Erqou S, Mohanty A, McGinnis KA, et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. J Viral Hepat 2013 July; 20: 463-9.
15. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol 2013; 11: 741-7.
16. Butt AA, Yan P, Bonilla H, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 2015; 62: 365-74.
17. Butt AA, Yan P, Lo Re V III, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175: 178-85.
18. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization. WHO/NMH/NHD/MNM/11 1 2011; Available at http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed 16 December, 2015.
19. Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10: 25-32.
20. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.